Kura Oncology (NASDAQ:KURA) Sets New 12-Month Low - Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $7.07 and last traded at $7.10, with a volume of 78892 shares. The stock had previously closed at $7.32.

Analyst Upgrades and Downgrades

KURA has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered their price target on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research note on Thursday, November 21st. JMP Securities restated a "market outperform" rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Stifel Nicolaus downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating and reduced their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. TD Cowen restated a "buy" rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.38.

Kura Oncology Stock Down 1.1 %

The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market cap of $563.01 million, a price-to-earnings ratio of -3.07 and a beta of 0.81. The firm's 50-day moving average is $11.56 and its 200 day moving average is $16.80.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC increased its position in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Armistice Capital LLC increased its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Geode Capital Management LLC raised its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after purchasing an additional 41,535 shares during the period. Franklin Resources Inc. raised its position in Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares during the period. Finally, Sofinnova Investments Inc. boosted its position in shares of Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company's stock worth $16,992,000 after buying an additional 323,303 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.